Over 95 percent of the study’s participants ceased their use of opioids by the conclusion of the study.
Topic: Health/Safety
Investigators identified “meaningful benefits” in patients’ sleep quality, pain, and nocturnal urinary frequency following cannabis treatment.
“Our findings fit within the broader literature showing that improved access to symptom-relieving treatments can affect labor market outcomes.”
“Cannabis-based medicines may offer an alternative to traditional treatments,” researchers concluded.
“Cannabis use for sleep is rising in popularity in the United States,” the study’s authors concluded.
The FDA’s decision follows the results of a Phase 3 clinical trial concluding that patients who consumed the cannabis extract experienced greater mean pain reductions than did those who took opioids.
“Clinically meaningful pain relief – defined as a ≥ 30 percent reduction in [patients’] average daily pain scores – was achieved by 70 percent of the treatment group.”
Testing reveals no significant differences between recreational users and abstainers in executive function and working memory.